Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, John H. Healey et al.|The Lancet|2019Cited by 472
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma MicroenvironmentTomohiro Fujiwara, John H. Healey, Mohamed A. Yakoub et al.|Molecular Cancer Therapeutics|2021Cited by 258
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.Richard Görlick, Barry Anderson, Peter M. Anderson et al.|PubMed|2003Cited by 198
The role of chemotherapy and radiotherapy in localized extraskeletal osteosarcomaMarilyn Heng, Akihiko Matsumine, Abha A. Gupta et al.|European Journal of Cancer|2019Cited by 79
Role of Tumor-Associated Macrophages in SarcomasTomohiro Fujiwara, Toshifumi Ozaki, John H. Healey et al.|Cancers|2021Cited by 54